

# Mindset Pharma discusses decision to expand into non-hallucinogenic drug discovery

NEWS RELEASE BY MINDSET PHARMA INC

**Toronto | March 31, 2023 12:36 PM Eastern Daylight Time**

Mindset Pharma CEO James Lanthier joins Proactive's Natalie Stoberman to discuss the company's latest update to expand into non-hallucinogenic therapeutic drug discovery.

Lanthier says Mindset has been one of the first biotech companies in the psychedelic space to apply state-of-the-art medicinal chemistry and behavioural pharmacology techniques to novel scaffolds of psychedelic drugs with the goal of discovering new medicines.

He adds that the company has been working towards discovering novel psychedelic-inspired non-hallucinogenic drug candidates and has found multiple candidates with a promising preclinical profile.



**Contact Details**

Proactive Canada

+1 604-688-8158

[na-editorial@proactiveinvestors.com](mailto:na-editorial@proactiveinvestors.com)

## Tags

PROACTIVEINVESTORS

MINDSETPHARMA

CSE

MSET

OTCQB

MSSTF

PSYCHEDELICS

NONHALLUCINOGENIC

BIOPHARMA

THERAPEUTICS

BIOTECH

INVEST

INVESTING

INVESTMENT

INVESTOR

STOCKMARKET

STOCKS

STOCK

STOCKMARKETNEWS